Etalocib
CAS No. : 161172-51-6
(Synonyms: LY293111; VML 295)
| Size | Price | Stock |
|---|---|---|
| 5mg | $330 | In-stock |
| 10mg | $495 | In-stock |
| 25mg | $890 | In-stock |
| 50mg | $1335 | In-stock |
| 100mg | $1870 | In-stock |
| 200 mg | Get quote | |
| 500 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-13628 |
| M.Wt: | 544.61 |
| Formula: | C33H33FO6 |
| Purity: | >98 % |
| Solubility: | DMSO : 100 mg/mL (ultrasonic) |
Etalocib (LY293111), an orally active leukotriene B4 receptor antagonist, inhibits the binding of [3H]LTB4, with a Ki of 25 nM. Etalocib (LY293111) prevents LTB4-induced calcium mobilization with an lC50 of 20 nM. Etalocib (LY293111) induces apoptosis[1][2][3].
In Vitro:Etalocib elicits a concentration-dependent inhibition of LTB4 induced CD11b up-regulation[1].
Etalocib is an extremely potent and selective antagonist of human neutrophil function in vitro[2].
Etalocib (250 and 500 nM, 24-72 h) induces apoptosis and inhibits proliferation in human pancreatic cancer cells[3].
In Vivo:Etalocib produces a dose-related inhibition of acute leukotriene B4-induced airway obstruction when administered i.v. (ED50=14 μg/kg) or p.o. (ED50=0.4 mg/kg)[2].
Etalocib (10 mg/kg) inhibits A23187-induced lung inflammatory changes at 1 h[2].
Etalocib (250 mg/kg/day, orally) inhibits growth of human pancreatic cancer xenografts in athymic mice[3].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- Etalocib
- Cat. No.:
- HY-13628
- Quantity:
Your information is safe with us.